



To Whom It May Concern

For ISO 15189:2012 and ISO 15189:2014 accredited Laboratories – requirements regarding “Calibration & Verification Procedures” [1]

All In vitro Diagnostics Products which are manufactured and distributed by Roche Diagnostics GmbH and for which a Free-Sales-Certificate is issued, are CE-marked.

The In-Vitro-Diagnostics Directive of the European Union [2] requires for all CE marked products that the manufacturer assures compliance of the products with the requirements of the In-Vitro-Diagnostics Directive. This means that all processes in development and manufacturing of Roche Diagnostics GmbH products are guided by a Quality Management System. Our Quality Management System is in compliance with the requirements from ISO 13485:2012 [3] + AC:2012 and 21 CFR Part 820 [4].

The mentioned regulations and standards require that the production systems and measuring devices used are qualified and the manufacturing and test procedures are validated. This status has to be assured by scheduled maintenance and by regular qualification resp. validation reviews and updates.

All physical quantities, calibrators and controls used in Roche Diagnostic systems are fully traceable to certified standards or reference materials. The performance of all In-vitro diagnostics systems of Roche Diagnostics GmbH at the customer site is assured if regular Quality Control measurements, cleaning and maintenance procedures as described in the instructions for use or service documentation are performed. By having controlled internal procedures and by running the tasks required in the respective user documentation, all In-vitro diagnostics systems of Roche Diagnostics GmbH will be performed as specified during their defined lifetime.

Additional calibration or verification procedures are NOT required of the user in order to assure the specified performance of every system of Roche Diagnostics GmbH. Only if a user deviates from these manufacturer's recommendations, the user have to establish site-specific calibration and verification procedures as part of his accreditation process.

Mannheim, 18 December 2017

Roche Diagnostics GmbH

Roche Diagnostics GmbH

Sandhofer Straße 116
D-68305 Mannheim

i.V. Andrea Weber
Project Manager Regulatory Affairs

ppa. Dr. Beate Bonefeld
Head of Quality Assurance Mannheim, CPS Quality

- [1] ISO 15189:2012/ ISO 15189:2014 Medical laboratories – Requirements for quality and competence
- [2] Directive 98/79/EC of the European Parliament and of the Council of the 27 October 1998 on vitro diagnostics medical devices
- [3] EN ISO 13485:2012 + AC:2012 Medical devices – Quality management systems-Requirements for regulatory purposes
- [4] CFR Part 820, Quality System regulations 21 Requirements on medical devices



Case No.	CAS-0013498922	Instrument Model	cobas b 221 6 Roche OMNI S6 system
Order No.	ORD-0017419449	Instrument Serial No.	26369
Contract Type	IN-WARRANTY	Finance Status	CASH
Lab/Inst./hosp.Name	Abirami Kidney Care		
Customer No.	0052606946		
Contact Name :	Saravanan T		
Contact Number :	+914242269495		
Address :	No.582, Brough Road,		
City :	Erode		

Call Received Date/Time:	22.05.2021 16:30	Call Attended Date/Time:	13.08.2021 09:15
--------------------------	------------------	--------------------------	------------------

Job Type	PM Visit
Job Description	
Action Summary	<p>Cause:PM Visit. Workdone:PM has been done as per the check list.Cleaned the instrument.Changed the PM Kit.Performed the calibration.Ran few samples. Verification:Machine working good. Customer Satisfaction Rating (1-5):5</p>

Spare Part Replaced					
Part No	Parts Description	Batch No	Batch Expiry Date	Qty	Invoice Type
05783461001 ⁽¹⁾	KIT-PM cobas b 221 < 2/ 4/ 6 > (YEARLY) ⁽¹⁾			1	Free of charge

⁽¹⁾: Customer owned

Time Report		
Effective Visit Date : 04.08.2021	Complete Date : 04.08.2021	
Date	Type	Time
2021.08.13	Travel Time--Standard	4.5
2021.08.13	Working Time--Standard	2.5
Total:		7

Customer's Signature Name : T Saravanan	Service Engineer/Application Specialist Name : Thamaraiselvan Subramani
Date: 05.08.2021	Date: 05.08.2021

Disclaimer
1. This Service report has been signed by the authorized representative of your organization.



2. Discrepancies if any must be intimated within a period of seven (7) days of the receipt of the email, in the absence of which the report will be final and conclusive.
3. This report shall be governed by the laws of India and the courts at Mumbai shall have the exclusive jurisdiction to deal with the disputes arising hereunder.